37 A key strength of STEP-HFpEF DM is its focus on the prevalent comorbidities of HFpEF and diabetes
The effects of L-carnitine supplementation on serum lipids: A systematic review and meta-analysis of randomized controlled trials

You may be an ideal candidate for GLP-1 weight-loss therapy if: You have a Body Mass Index (BMI) of 30 or higher, indicating obesity You have a BMI of 27 or higher and at least one weight-related medical condition, such as: High blood pressure (hypertension) High cholesterol or triglycerides Type 2 diabetes or pre-diabetes Obstructive sleep apnea Heart disease or increased cardiovascular risk factors You have tried traditional weight-loss methods (diet, exercise) without sustained success Youre seeking medically supervised weight management, especially if other approaches have been ineffective You are committed to lifestyle modifications, including dietary changes, increased physical activity, and regular follow-ups During your consultation, well comprehensively evaluate your medical history, current health status, and weight-loss goals to determine if GLP-1 therapy is right for you
, - ,
5, while S 1 is the statistical result of the standard deviation of the blank solution and a is the blank value
For patients with established IBD, the gastrointestinal side effects of full-dose GLP-1 therapy can be problematic